Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Gains from Sales and Divestitures (2019 - 2025)

Regenxbio (RGNX) has 5 years of Gains from Sales and Divestitures data on record, last reported at $743000.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 88.1% year-over-year to $743000.0; the TTM value through Dec 2025 reached $743000.0, up 88.1%, while the annual FY2025 figure was $743000.0, 88.1% up from the prior year.
  • Gains from Sales and Divestitures reached $743000.0 in Q4 2025 per RGNX's latest filing, up from $732000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $743000.0 in Q4 2025 and bottomed at $68.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 4 years is $306191.8, with a median of $252000.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 269017.65% in 2023, then soared 67.04% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $68.0 in 2022, then skyrocketed by 269017.65% to $183000.0 in 2023, then surged by 115.85% to $395000.0 in 2024, then skyrocketed by 88.1% to $743000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $743000.0 in Q4 2025, $732000.0 in Q3 2025, and $598000.0 in Q2 2025.